Fedora Pharmaceuticals Inc
Fedora Pharmaceuticals Inc., founded in 2011 and headquartered in Edmonton, Alberta, is dedicated to addressing the global challenge of antimicrobial resistance (AMR) through the discovery and development of novel antimicrobial agents. The company has a robust pipeline of antibiotic candidates, with Nacubactam being its most advanced product, designed to inhibit beta-lactamases that compromise the effectiveness of many commonly prescribed antibiotics.
With a management and scientific team rich in expertise in drug discovery and development, Fedora is committed to advancing innovative solutions to combat multidrug-resistant pathogens. The company aims to select one or more antibiotic candidates for clinical trials by 2022, contributing to the fight against antibiotic-resistant infections that pose a significant threat to global health.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.
